NEW HAVEN, Conn., Sept. 9 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. (“Rib-X” or the “Company”), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today the formation of its Clinical Advisory Board. The Board, comprised of six infectious disease specialists, will provide oversight and counsel on matters related to the Company’s clinical development programs.
Dr. Robert C. Moellering, Jr., M.D., will serve as Chairman of the Clinical Advisory Board. From 1999 to 2005, Dr. Moellering was the Herrman L. Blumgart Professor of Medicine at Harvard Medical School and Chairman of the Department of Medicine at Beth Israel Deaconess Medical Center, Boston. He now holds the Shields Warren-Mallinckrodt Chair of Medical Research at Harvard Medical School, and was the founder and served as the CEO of the Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center until 2004.
Other individuals named to the Advisory Board include:
-- Helen W. Boucher, M.D., Assistant Professor of Medicine, Tufts University School of Medicine, Director of the Infectious Diseases Fellowship Program, and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, Boston;
-- Henry F. Chambers, M.D., Chief Professor of Medicine in the Division of Infectious Diseases at San Francisco General Hospital, and the Director of the University of California, San Francisco Infectious Diseases Fellowship Training Program;
-- Barbara E. Murray, M.D., Director of the Division of Infectious Diseases at the University of Texas-Houston Medical School, and Co-Director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens;
-- Leon G. Smith, M.D., Professor of Medicine and Preventive Medicine / Community Health at the University of Medicine and Dentistry of New Jersey, Chair of the Residency Program in Internal Medicine at Seton Hall University School of Graduate Medical Education, and the Director of Medicine and Chief of Infectious Disease at St. Michael’s Medical Center;
-- Richard P. Wenzel, M.D., M.Sc., Professor and Chairman of the Department of Internal Medicine, Senior Associate Dean for Clinical Affairs, and President of MCV Physicians at the Medical College of Virginia/Virginia Commonwealth University in Richmond, Virginia.
“This world-class Advisory Board was attracted to the Rib-X mission of discovering and developing new therapies for life-threatening, resistant bacterial infections, and we are proud to have them as colleagues and advisors at this important time in our growth,” said Susan Froshauer, Ph.D, President and CEO of Rib-X. “The formation of the Clinical Advisory Board is indicative of our evolution as a Company and we look forward to working with these board members to advance our clinical programs.”
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company’s underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company’s integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X’s iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. Radezolid (RX-1741), an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections. The RX-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the RX-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococci pneumonia and S. pyogenes. Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active against a broad spectrum of bacteria, including quinolone resistant Gram positive bacteria and MRSA. Both radezolid and delafloxacin are currently in Phase 2 clinical trials.
For more information on the ribosome and the Rib-X mission, please visit the Company website at www.rib-x.com.
CONTACT: Investors, John Capodanno, FD Life Sciences, +1-212-850-5705,
John.capodanno@fd.com, or Media, Irma Gomez-Dib, FD Life Sciences,
+1-212-850-5761, irma.gomez-dib@fd.com
Web site: http://www.rib-x.com/
